Wednesday July 15, 10:38 am Eastern Time
Company Press Release
SOURCE: Paracelsian Inc.
Paracelsian Files BioFIT Patent Application
ITHACA, N.Y., July 15 /PRNewswire/ -- (Nasdaq: PRLN - news) Paracelsian, Inc. (http://www.paracelsian.com)
announced today that it has filed a patent application covering its BioFit ''functional'' quality assurance
testing program. The application was filed through Paracelsian's patent counsel, Kenyon and Kenyon of New
York City.
The BioFIT testing program is a unique testing program through which Paracelsian is able to certify consistent bio-functionality of herbal and other dietary supplements. Once the product has been confirmed as having the appropriate level of biological activity relevant to the benefit claims on its label, Paracelsian awards the BioFIT
Certification. The certification allows the use of the BioFIT logo on product labels, packaging and promotional
materials thus helping consumers make a better, more informed choice about which product will deliver the
benefits they are seeking.
''The BioFIT Certification helps take the guess work out of purchasing herbal supplements'' said Bernie Landes, President and CEO of Paracelsian. ''The filing of this Patent application is part of our ongoing program to insure that BioFIT becomes the new standard of quality for the herbal supplement industry, not just in the
United States, but worldwide. We will be filing the appropriate International Patent applications promptly,'' he concluded.
On July 9, 1998 Paracelsian announced a strategic alliance with R.P. Scherer North America, a division of R.P. Scherer Corporation for the marketing and distribution of its BioFIT ''Functional'' Certification Program. The agreement further calls for the prompt negotiation of a worldwide agreement.
Paracelsian is a unique biotechnology company whose business centers on the development and application of functional bioassays. These assays are used for Quality Assurance of herbs, botanicals and other dietary supplements, in the development of dietary supplements, OTC and pharmaceutical products, and in monitoring environmental toxins and identifying carcinogens.
Notice: This news release may contain forward-looking statements. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange
Commission.
No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.
SOURCE: Paracelsian Inc.
|
